The Heranova trial in China is the most exciting aspect of MEM's current and future prospects IMO.
China is the one of the biggest markets globally for IVF, if not the biggest, and as per the above attached posts, China has active government policies which are promoting child birth within the declining population of China.
IMO, all things seem well aligned for MEM and Heranova to provide Felix as commercial solution to China's declining population problem. Interestingly, China is also globally known as a factory production powerhouse....and can produce products at a relatively cheap cost by global standards......so any commercial agreement between MEM and Heranova could also easily include the production of the Felix System in China at a relatively inexpensive cost of production (so many factories in China looking for new customers).
The Heranova study aims to test 50 patients in China and has been ongoing now for about 3 months. I can't imagine it would take long to complete a trial of 50 patients in China, considering they have such a large population (1.4 billion people).
IMO, an update on the Heranova agreement could be just around the corner......and could be potentially transformative for MEM as a company.
